MTOR and clear cell renal carcinoma: Before the introduction of the more recent immunologic therapies for metastatic clear cell renal carcinoma (metastatic CCRC), antiangiogenic and anti-mammalian target of rapamycin (mTOR) agents represented the cornerstone of treatment for over 10 years [9,10].